| Literature DB >> 33726017 |
Jee Hye Wee1, Woo Jin Bang2, Min Woo Park3, Soo-Hwan Byun4, Hyo Geun Choi1,5.
Abstract
ABSTRACT: The purpose of this study was to evaluate the association between asthma and benign prostatic hyperplasia (BPH) in an adult Korean population and to evaluate this association based on the treatment status of asthmatics.We utilized the Korean genome and epidemiology study health examinee 2004 to 2016 database. A total of 47,186 participants (825 asthmatics and 46,361 controls) were selected and their BPH histories were analyzed. We categorized the participants according to their asthma treatment status: "well controlled"; "being treated"; and "not being treated". The adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for BPH were analyzed using multiple logistic regression. Subgroup analyses were performed according to age (60 years).The results showed that the prevalence of BPH was higher among asthma patients (17.1%) than among controls (8.7%, P < .001). Asthma patients had a higher risk of having BPH (OR = 1.64, 95% CI = 1.37-2.01, P < .001) than controls, after adjustment for age, income, body mass index (BMI), smoking, alcohol consumption, frequency of physical activity, and the past medical diseases. The ORs for BPH were 1.35 (95% CI = 1.04-1.76) in those aged >60 years and 2.24 (95% CI = 1.70-2.96) in those aged ≤60 years. The ORs for BPH were 1.82 (95% CI = 1.16-2.87, P = .009) in the "well-controlled" group, 1.05 (95% CI = 0.74-1.49, P = .794) in the "being treated" group, and 2.24 (95% CI = 1.69-2.97, P < .001) in the "not being treated" group.We found that there is a correlation between asthma and BPH in the adult Korean population. There is a stronger association between asthma and BPH in younger adults and in those who are not receiving treatment for asthma.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33726017 PMCID: PMC7982242 DOI: 10.1097/MD.0000000000025214
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Figure 1A schematic illustration of the participant selection process that was used in the present study. A total of 47,186 participants were selected.
General characteristics of participants.
| Total participants | |||
| Characteristics | Asthma (n = 825) | Control (n = 46,361) | |
| Age (mean, SD, y) | 57.4 (8.8) | 54.1 (8.7) | <.001∗ |
| BMI (mean, SD, kg/m2) | 24.6 (3.0) | 24.4 (2.7) | .060 |
| Income (n, %) | <.001∗ | ||
| Missing, no response | 118 (14.3) | 4,667 (10.1) | |
| Lowest | 247 (29.9) | 11,319 (24.4) | |
| Middle | 270 (32.7) | 18,553 (40.0) | |
| Highest | 190 (23.0) | 11,822 (25.5) | |
| Smoking status (n, %) | <.001∗ | ||
| Nonsmoker | 240 (29.1) | 12,906 (27.8) | |
| Past smoker | 399 (48.4) | 18,978 (40.9) | |
| Current smoker | 186 (22.5) | 14,477 (31.2) | |
| Alcohol consumption (n, %) | <.001∗ | ||
| Non drinker | 209 (25.3) | 9,263 (20.0) | |
| Past drinker | 96 (11.6) | 3,462 (7.5) | |
| Current drinker | 520 (63.0) | 33,636 (72.5) | |
| Physical activity (n, %) | .048∗ | ||
| 0 times a week | 371 (45.0) | 20,512 (44.2) | |
| 1–2 times a week | 116 (14.1) | 8,231 (17.8) | |
| 3–4 times a week | 154 (18.7) | 8,572 (18.5) | |
| 5–6 times a week | 83 (10.1) | 4,112 (8.9) | |
| 7 times a week | 101 (12.2) | 4,934 (10.6) | |
| Hypertension | 277 (33.6) | 12,611 (27.2) | <.001∗ |
| Diabetes mellitus | 135 (16.4) | 5,249 (11.3) | <.001∗ |
| Hyperlipidemia | 154 (18.7) | 6,334 (13.7) | <.001∗ |
| Cerebral stroke | 28 (3.4) | 982 (2.1) | .012∗ |
| Ischemic heart disease | 71 (8.6) | 2,139 (4.6) | <.001∗ |
| Benign prostate hyperplasia | 141 (17.1) | 4,019 (8.7) | <.001∗ |
Independent t test or Chi-Square test. Significance at P < .05.
Crude and adjusted odds ratios (95% confidence interval) for benign prostate hyperplasia in asthma and control groups.
| Odds ratios for benign prostate hyperplasia | ||||
| Characteristics | Crude | Adjusted† | ||
| Total participants (n = 47,186) | ||||
| Asthma | 2.17 (1.81–2.61) | <.001∗ | 1.64 (1.37–2.01) | <.001∗ |
| Control | 1.00 | 1.00 | ||
| Age ≤60 years old (n = 34,391) | ||||
| Asthma | 3.63 (2.47–5.34) | .001∗ | 2.24 (1.70–2.96) | <.001∗ |
| Control | 1.00 | 1.00 | ||
| Age >60 years old (n = 12,795) | ||||
| Asthma | 1.59 (1.29–1.96) | <.001∗ | 1.35 (1.04–1.76) | .023∗ |
| Control | 1.00 | 1.00 | ||
Logistic regression model, Significance at P < .05.
Models adjusted for age, income group, BMI, smoking, alcohol consumption, frequency of physical activity, and the past medical histories (hypertension, diabetes mellitus, hyperlipidemia, cerebral stroke, and ischemic heart disease).
Crude and adjusted odds ratios (95% confidence interval) for benign prostate hyperplasia by the condition of asthma treatment.
| Odds ratios for benign prostate hyperplasia | ||||
| Characteristics | Crude | Adjusted† | ||
| Total participants (n = 45,075) | ||||
| Well controlled | 2.23 (1.44–3.43) | <.001∗ | 1.82 (1.16–2.87) | .009∗ |
| Being treated | 1.50 (1.07–2.11) | .019∗ | 1.05 (0.74–1.49) | .794 |
| Not being treated | 2.70 (2.07–3.52) | <.001∗ | 2.24 (1.69–2.97) | <.001∗ |
| Control | 1.00 | 1.00 | ||
| Age ≤ 60 years old (n = 32,915) | ||||
| Well controlled | 1.80 (0.56–5.77) | .326 | 2.03 (1.03–4.00) | .041∗ |
| Being treated | 3.19 (1.53–6.64) | .002∗ | 1.59 (0.96–2.62) | .071 |
| Not being treated | 4.85 (2.93–8.03) | <.001∗ | 3.01 (2.03–4.45) | <.001∗ |
| Control | 1.00 | 1.00 | ||
| Age ≥ 60 years old (n = 12,160) | ||||
| Well controlled | 2.01 (1.24–3.25) | .004∗ | 1.76 (0.96–3.20) | .067 |
| Being treated | 0.98 (0.67–1.44) | .918 | 0.79 (0.49–1.27) | .331 |
| Not being treated | 2.01 (1.46–2.76) | <.001∗ | 1.77 (1.20–2.62) | .004∗ |
| Control | 1.00 | 1.00 | ||
Logistic regression model, significance at P < .05.
Models adjusted for age, income group, BMI, smoking, alcohol consumption, frequency of physical activity, and the past medical histories (hypertension, diabetes mellitus, hyperlipidemia, cerebral stroke, and ischemic heart disease).